Summary. Principal stratification is a causal framework to analyze randomized experiments with a post-treatment variable between the treatment and endpoint variables. Because the principal strata defined by the potential outcomes of the post-treatment variable are not observable, we generally cannot identify the causal effects within principal strata. Motivated by a real data set of phase III adjuvant colon clinical trials, we propose approaches to identifying and estimating the principal causal effects via multiple trials. For the identifiability, we remove the commonly-used exclusion restriction assumption by stipulating that the principal causal effects are homogeneous across these trials. To remove another commonly-used monotonicity assumption, we give a necessary condition for the local identifiability, which requires at least three trials. Applying our approaches to the data from adjuvant colon clinical trials, we find that the commonly-used monotonicity assumption is untenable, and disease-free survival with three-year follow-up is a valid surrogate endpoint for overall survival with five-year follow-up, which satisfies both the causal necessity and the causal sufficiency. We also propose a sensitivity analysis approach based on Bayesian hierarchical models to investigate the impact of the deviation from the homogeneity assumption.
Introduction

Principal stratification and surrogate endpoints
Causal effects are defined as comparisons between potential outcomes of the endpoint variable under treatment and control for the same group of individuals. To evaluate the causal effects on the endpoint within subpopulations stratified by a post-treatment variable, Frangakis and Rubin (2002) proposed the principal stratification framework in which the subpopulations are defined by the joint values of the potential outcomes instead of the observed value of the post-treatment variable. The joint potential outcomes of the post-treatment variable can be viewed as a pretreatment covariate vector unaffected by the treatment. Principal stratification has several applications in the current literature. The compliance behavior defined by the potential treatment acceptances is used to address the noncompliance problem (Angrist et al., 1996) , the potential survival status is used to evaluate the effect on the quality of life with truncation by death (Rubin, 2006; Ding et al., 2011; Yang and Small, 2015) , and the potential employment status is used to deal with the truncation of wages due to unemployment in the evaluation of job-training programs (Zhang and Rubin, 2003; Zhang et al., 2009; Frumento et al., 2012) . The potential response indicators are used to address non-ignorable nonresponse problems (Frangakis and Rubin, 1999; Mealli and Pacini, 2008; Mattei et al., 2014) , and the potential intermediate variables are used to define direct and indirect effects (Rubin, 2004; Gallop et al., 2009; Mattei and Mealli, 2011) .
Another important application of principal stratification is to evaluate surrogate endpoints in clinical trials (Frangakis and Rubin, 2002) . When direct measurement of an endpoint of interest is too time-consuming or costly, we try to measure a surrogate for the endpoint. There have been some criteria for judging surrogates from different points of view. Prentice (1989) first proposed the statistical surrogate criterion, which requires conditional independence of the treatment and the observed endpoint given the observed surrogate. From a causal perspective, Frangakis and Rubin (2002) proposed the principal surrogate criterion, and pointed out that the statistical surrogate does not satisfy the causal necessity, i.e., no difference between the potential outcomes of the surrogate implies no difference between the potential outcomes of the endpoint. Lauritzen (2004) proposed the strong surrogate criterion depicted by a causal diagram requiring the surrogate break the causal path from the treatment to the endpoint, which is stronger than the principal surrogate. Gilbert and Hudgens (2008) argued that a principal surrogate should satisfy not only causal necessity but also causal sufficiency. The causal sufficiency requires that if the treatment effect on the surrogate is nonzero, then the treatment effect on the endpoint is also non-zero. Joffe and Greene (2009) considered four different approaches for evaluating surrogate endpoints. However, all of these approaches may suffer from the surrogate paradox as pointed out by Chen et al. (2007) , Ju and Geng (2010) and VanderWeele (2013) . That is, for a surrogate satisfying any of these criteria, it is possible that the treatment has a negative average causal effect on the endpoint even if the treatment has a positive average causal effect on the surrogate and the surrogate has a positive average causal effect on the endpoint.
For evaluating surrogates, Mealli and Mattei (2012) suggested conducting a principal stratification analysis investigating the effect of the treatment within all principal strata. However, because we cannot simultaneously observe two potential outcomes of the post-treatment variable, we do not know the principal stratum of an individual, and generally we cannot identify causal effects within principal strata. Zhang and Rubin (2003) and Cheng and Small (2006) proposed large sample bounds of causal effects within some principal strata, which, however, may be too wide to be informative. Angrist et al. (1996) discussed the identifiability of the complier average causal effect under the monotonicity and exclusion restriction assumptions. Without the exclusion restriction assumption, Zhang et al. (2009) used Gaussian mixture models to identify causal effects within principal strata. Gilbert and Hudgens (2008) and Huang and Gilbert (2011) proposed approaches to evaluating surrogates based on principal stratification in a single trial, but they assumed constant potential outcomes of the surrogate under control. Zigler and Belin (2012) proposed a Bayesian approach to estimating the causal effects on the endpoint within principal strata without the monotonicity assumption, but their approach relied on prior distributions on some parameters that are not identifiable.
Motivation
Our study is motivated by the data from phase III adjuvant colon clinical trials (ACCTs). The goal of the ACCTs is to test whether disease-free survival (DFS) with three-year follow-up can be used as a surrogate for the overall survival (OS) with five-year follow-up (Sargent et al., 2005) . The data are collected from 10 clinical trials. Sargent et al. (2005) found a strong correlation between the hazard ratio of the treatment on DFS and the hazard ratio of the treatment on OS. Applying a meta-analysis, Baker et al. (2012) used DFS as a principal surrogate to predict the treatment effect on the endpoint using the treatment effect on the surrogate. They assumed that the true endpoint does not depend on the treatment among subjects whose surrogate is the same under treatment and control, i.e., the causal necessity holds. However, the causal necessity used by Baker et al. (2012) has not been verified by either previous studies or observed data.
For the ACCTs data, the monotonicity assumption requiring nonnegative individual causal effect on the surrogate may not hold, because the treatment may have negative side-effects on the surrogate for some patients. Second, the exclusion restriction assumption implies the causal necessity, which is the scientific question of interest in evaluating surrogate endpoints. Third, Gaussian mixture models are not applicable to the binary endpoints in the ACCTs data. The metaanalysis approaches (Daniels and Hughes, 1997; Li et al., 2011; Baker et al., 2012) may also suffer from the surrogate paradox (VanderWeele, 2013) . When the monotonicity or exclusion restriction assumption does not hold, Ding et al. (2011) , Mealli and Pacini (2013) , and Yang and Small (2015) achieved partial and point identification of principal causal effects by exploiting covariates or secondary outcomes, and Mattei et al. (2013) improved Bayesian inference for principal causal effects using multiple outcomes. However, when additional outcomes or covariates are not available, we cannot identify causal effects using previous approaches. Without identifiability, Bayesian inference is sensitive to prior distributions (Gustafson, 2009) .
In this paper, we propose approaches to identifying the principal stratification causal effects without the exclusion restriction assumption and further without the monotonicity assumption. To remove the exclusion restriction assumption, we need at least two trials. Furthermore, to remove the monotonicity assumption, we give a sufficient condition for the local identifiability of the causal effects, which requires at least three trials. We first assume that these trials are homogeneous. Using the identified principal stratification causal effects, we can test the causal necessity and the causal sufficiency of a surrogate. We evaluate the treatment effect on the unobserved endpoint in a new trial where the distribution of principal strata and/or the treatment may be different from those in the validation trials. We then propose criteria for surrogates that avoid the surrogate paradox. Allowing for possible deviations from the homogeneity assumption, we then conduct a sensitivity analysis based on a class of Bayesian hierarchical models. We apply the proposed approaches to the ACCTs data and evaluate the surrogacy of DFS with three-year follow-up for OS with five-year follow-up.
The paper proceeds as follows. We introduce the notation and assumptions in Section 2. We present the identification conditions with and without the monotonicity assumption in Section 3. Section 4 discusses the evaluation of surrogate based on principal stratification. We evaluate the performance of our approaches with finite sample sizes in Section 5 via simulation studies. We apply our approaches to the ACCTs data in Section 6, and perform a sensitivity analysis using Bayesian hierarchical models in Section 7. We conclude with a discussion in Section 8. We present the details of the proofs and computations in the online supporting materials, and provide the data and compute code online. Definition 1. Causal necessity requires ACE ur = 0 for u = ss,ss, and causal sufficiency requires ACE ur = 0 for u = ss,ss, where r = 1, . . . , N R .
The above definition of causal necessity is weaker than the usual exclusion restriction assumption (Angrist et al., 1996) that requires zero individual causal effect on the outcome for principal strata u = ss andss.
Assumptions
In this subsection, we introduce the basic assumptions, which are commonly used in causal inference. By identification of parameters, we mean that they can be expressed as functions of the distributions of observed variables. We let A B | C denote the conditional independence of A and B given C.
Assumption 1 means that treatment assignment Z is randomized within each trial, but the assignment probabilities may be different. Because we have independent randomized clinical trials in the ACCTs data, Assumption 1 holds by the designs of experiments.
The following monotonicity assumption is widely used for principal stratification analysis (Angrist et al., 1996) and principal surrogate evaluation (Gilbert and Hudgens, 2008) .
Assumption 2 means that the treated surrogate endpoint S i (1) is always better than or equal to the controlled surrogate endpoint S i (0) for every patient i. The monotonicity assumption may be too restrictive for some real applications where treatment may have negative side-effects on some patients. We shall discuss the identification of PSACEs with and without the monotonicity assumption separately.
Let O(z, s) denote the set of principal strata that are compatible with the observed values Z i = z and S i = s. Then we have O(1, 1) = {ss, ss}, O(1, 0) = {ss,ss}, O(0, 1) = {ss,ss}, and O(0, 0) = {ss,ss} without the monotonicity assumption. The monotonicity assumption eliminates the stratumss, and therefore O(1, 1) = {ss, ss}, O(1, 0) = {ss}, O(0, 1) = {ss}, and O(0, 0) = {ss,ss}. Although the principal stratification variable U is not observable for all units, monotonicity allows us to identify the proportions of principal strata using the distribution of the observed data. Define
which can be identified by πss ,r = P (S = 0 | Z = 1, R = r), π ss,r = P (S = 1 | Z = 0, R = r) and π ss,r = 1 − π ss,r − πss ,r . With monotonicity, we can also identify the expectations
Since patients within the observed group (Z = 1, S = 1) or (Z = 0, S = 0) are both mixtures of two latent principal strata, we cannot identify the PSACEs without further assumptions beyond Assumptions 1 and 2. We can obtain large sample bounds for the PSACEs from the observed data, but these bounds are barely informative as shown in the online Appendix.
Identification of the PSACEs from multiple trials
Because the principal stratum is unobservable, causal effects within principal strata are not identifiable in general. In this section, we shall propose approaches to improving the identifiability of the PSACEs in terms of multiple trials. To combine information from multiple trials, we make the following homogeneity assumption.
The homogeneity assumption means that the potential outcome Y (z) may depend on the principal stratum U , but is independent of the trial number R conditional on the principal stratum U . Thus, there is no "direct effect" of R on Y (z) within the principal stratum U . We can include pretreatment covariates X to make this assumption more plausible, i.e., R Y (z) | (U, X), and we omit it for simplicity. As an example, Assumption 3 for the ACCTs data means that the survival of a patient under treatment or control does not depend on which trial he/she is in once we know his/her principal stratum U , defined by the reoccurrence of cancer under both treatment and control. In particular, for the patients in stratum U = ss, the cancer will not reoccur within 3 years no matter whether they receive the treatment or not. Thus the principal stratum can be interpreted as a measure of the physical status of a patient. It may be plausible that the survival will no longer depend on the trial number after we know a patient's physical status and the cancer status.
Recognizing that Assumption 3 may not be directly testable and may be violated in practice, we propose an approach for conducting sensitivity analysis about Assumption 3 in Section 7.
The following result further explains the homogeneity of causal effects across trials.
Proposition 1. Under Assumption 1, Assumption 3 is equivalent to R Y | (U, Z), which implies ACE ur = ACE ur for all u = ss, ss,ss,ss and r = r .
By Proposition 1, we can write ACE u = ACE ur , and thus we can discuss the identifiability of the common PSACEs using the data from multiple trials together.
To simplify the notation, we define p r = P (R = r) as the proportion of trial r, α r = P (Z = 1 | R = r) as the proportion of patients receiving treatment in trial r, δ zur = P (Y = 1 | Z = z, U = u, R = r) as the survival proportion conditional on the treatment z, principal stratum u and trial number r. Under the homogeneity assumption, we have that δ zu = δ zur . We further define p = {p r : r = 1, . . . , N R }, α = {α r : r = 1, . . . , N R }, π r = {π ss,r , π ss,r , πss ,r , πs s,r }, π = {π r : r = 1, . . . , N R }, and δ = {δ zu : z = 0, 1; u = ss, ss,ss,ss}. Under monotonicity, we do not have the parameters δ z,ss , and we have πs s,r = 0.
Identification with monotonicity
In addition to the homogeneity assumption, we need the following assumption.
Assumption 4. (a) There exist at least two trials r 1 and r 2 , such that π ss,r1 /π ss,r1 = π ss,r2 /π ss,r2 . (b) There exist at least two trials r 3 and r 4 , such that π ss,r3 /πss ,r3 = π ss,r4 /πss ,r4 .
Again, treating the principal stratum as a measure of patients' physical status, Assumption 4 means that patients in different trials have different distributions of the patients' physical status. Under monotonicity, Assumption 4 is testable by data because we can identify the proportions of the principal strata under Assumption 2 as shown in Section 2.2.
The trial number R acts like an instrumental variable associated with U in the sense that Assumption 3 is similar to the exclusion restriction assumption, and Assumption 4 guarantees the association between R and U . Under Assumptions 3 and 4, there is no "direct effect" of R on Y , which is similar to the instrumental variable case where the instrumental variable does not "directly" affect the outcome. Assumption 4 requires at least two independent trials for the identifiability. We can use any two trials satisfying Assumption 4 to obtain moment estimators, and we can also use all trials to obtain more efficient maximum likelihood estimates (MLEs). The following example illustrates the identifiability for the case with two independent trials (N R = 2) under Assumptions 1 to 4. Example 1. First, the proportions of the principal strata π ur are identifiable under monotonicity, as discussed in Section 2.2.
Second, the probability ω ys|zr = P (Y = y, S = s | Z = z, R = r) can be identified from the observed data. We can directly identify two outcome distributions δ 1,ss = ω 10|11 /πss ,1 and δ 0,ss = ω 11|01 /π ss,1 .
Third, if π ss,1 /π ss,1 = π ss,2 /π ss,2 , we have from the proof of Theorem 2 that
If π ss,1 /π ss,1 = π ss,2 /π ss,2 , we have from the proof of Theorem 2 that
Identification without monotonicity
Monotonicity for every individual may be too restrictive in practice. In this subsection, with the help of more than two independent trials, we can remove monotonicity. By the homogeneity assumption, the probabilities of the observed data can be decomposed as
for z, s, y = 0, 1. Let ξ = (p, α, π, δ) denote the vector of the parameters. Let f be the vector of probabilities on the left-hand side of equation (B.1). Applying a Taylor expansion, we can approximate f (ξ) by linear equations of ξ around the true parameters ξ 0 , i.e., f (ξ) ≈ f (ξ 0 )+∇f | ξ0 (ξ − ξ 0 ), where ∇f | ξ0 is the Jacobian matrix with the (i, j)-th element ∂f i /∂ξ j | ξ0 . According to Roche et al. (1997) , a distribution F W (w; ξ) of a random variable W is locally identifiable at ξ 0 if there exists some neighborhood N (ξ 0 ) of ξ 0 such that for all ξ ∈ N (ξ 0 ), F W (w; ξ 0 ) = F W (w; ξ) for all w if and only if ξ = ξ 0 . Therefore, under the randomization and homogeneity assumptions, the parameter vector ξ can be represented by a function of the distributions of observed variables and thus it is locally identifiable if the Jacobian matrix ∇f | ξ0 is of full column rank. In fact, Assumption 4 is a necessary condition for ∇f | ξ0 to be full column rank. In practice, the full rank condition of ∇f | ξ0 can be tested empirically by the rank of ∇f |ξ, whereξ is the MLE of ξ 0 (Goodman, 1974; Skrondal and Rabe-Hesketh, 2004) . A necessary condition for local identifiability of unknown parameters is that the number of observed frequencies is larger than the number of unknown parameters. For this case, we have the following result.
Proposition 2. Under Assumptions 1 and 3, a necessary condition for the local identifiability of the joint distribution of (Y, Z, S, U, R) is N R ≥ 3.
Intuitively, when N R ≤ 2, there will be less equations than unknown parameters in the equations in (B.1), and thus we cannot obtain unique solution of the unknown parameters. Therefore, there must be at least three independent trials to identify the PSACEs without monotonicity. In the case without monotonicity, we can not obtain closed forms of PSACEs like Example 1, because we are not able to obtain closed forms of π ur 's. We can use a numerical approach to calculate the PSACEs, and we give an example in the online Appendix to illustrate the identifiability for the case without monotonicity.
Without monotonicity, we can prove only local identification. If a parameter is locally identifiable but not globally identifiable, its posterior distribution must be multimodal and has the same value at multiple modes. Thus, we can check its posterior distribution to verify identifiability. In our simulation studies and application, posterior distributions of all the parameters are unimodal, which means that the parameters are indeed globally identifiable. In general, we can test whether the posterior distributions of parameters are unimodal using existing methods.
Computation, model checking, and goodness-of-fit tests
In this subsection, we shall discuss the estimation of the parameters. We can use the expectationmaximization (EM) algorithm and the Gibbs Sampler to compute the MLEs and simulate the posterior distributions of PSACEs. Suppose that R follows a categorical distribution with parameter p, Z follows Bernoulli distributions conditional on R with parameter α, U follows categorical distributions conditional on R with parameter π, and Y follows Bernoulli distributions conditional on Z and U with parameter δ. The unobserved variable U is treated as a latent variable. The complete data can be represented by a contingency table classified by (Z, U, Y, R), and the observed data can be represented by a contingency table classified by (Z, S, Y, R) with cell counts N zsyr = #{i :
For Bayesian inference, we use Dirichlet (or Beta) distributions with parameters (1, . . . , 1) as the non-informative prior distributions of p, α, π and δ. Computational details are given in the online Appendix.
More interestingly, when N R ≥ 2 with monotonicity or N R ≥ 3 for without monotonicity, the extra degrees of freedom allow us to perform goodness-of-fit tests based on the asymptotic distributions of the likelihood ratio statistics:
whereζ s is the MLE under the saturated model, i.e., (Z, S, R, Y ) follows the multinomial distribution without constraints on parameters, andξ m andξ nm are the MLEs with and without monotonicity. The degrees of freedom with and without monotonicity are (
On the other hand, we can use Bayesian posterior predictive p-values (ppp) for model checking (Rubin, 1984; Meng, 1994) . Let N rep zsyr denote the replicate data generated from their posterior predictive distributions. The ppp's for the models with and without monotonicity are
which can be approximated by the posterior draws from the Gibbs Sampler.
Evaluation of surrogate based on principal stratification
In the previous section, we proposed approaches to identifying the PSACEs using multiple trials. In this section, our goal is to predict the treatment effect on the endpoint both quantitatively and qualitatively, based on the treatment effect on the surrogate in a new trial without observing the endpoint. We consider two cases for applying the principal surrogate to a new trial in which the endpoint is not observed. Case 1. The surrogate is applied to a new population where the treatment is the same, but the distribution of principal strata differs from the validation trials. For example, in validation trials, we study the effect of drug A on cardiovascular disease, and use an indicator for whether the level of cholesterol increases as a candidate surrogate. Based on the PSACEs estimated from validation trials, we use the surrogate to predict the effect of the drug A on the disease of patients in a different population.
Case 2. The surrogate is applied to a new population where both the treatment and the distribution of principal strata may be different from those in the validation trials. For example, based on the PSACEs for drug A estimated from validation trials, we use the surrogate to predict the effect of a new drug B on the disease of patients in a different population.
For quantitative evaluation, we assume that the PSACEs are the same across the validation trials and the new trial, then try to calculate the treatment effect on the endpoint. For qualitative evaluation, we relax this assumption so that the PSACEs have the same signs across the validation trials and the new trial. Then we try to get the sign of the the treatment effect on the endpoint.
VanderWeele (2013) points out that a principal surrogate satisfying the causal necessity (ACE u = 0 for u = ss,ss) and the causal sufficiency (ACE u = 0 for u = ss,ss) may not avoid the surrogate paradox. In the following example, we further illustrate that a principal surrogate verified in a validation trial may not be used to correctly evaluate the treatment effect on the unobserved endpoint in a new trial, even if the new trial and the validation trials have the same PSACEs.
Example 2. Consider a surrogate S which is evaluated by validation trial r. The surrogate satisfies the causal necessity with ACE ss = ACEss = 0, and the causal sufficiency with ACE ss = 0.4 and ACEs s = −0.6. Suppose that the distribution of principal strata in the validation trial is π ss,r = πss ,r = 0.2, π ss,r = 0.4 and πs s,r = 0.2. Then we have E{S(1)−S(0) | R = r} = 0.2 > 0 and E{Y (1)−Y (0) | R = r} = 0.04 > 0, which means that the surrogate paradox is avoided in validation trial r. Now suppose that a new trial R = r has the same PSACEs as the validation trial. But the distribution of principal strata differs: π ss,r = 0.1, πss ,r = 0.2, π ss,r = 0.4, and πs s,r = 0.3.
The surrogate paradox arises, and thus we cannot use the surrogate S to correctly evaluate the treatment effect on the endpoint Y in the new trial. Now we discuss the conditions to avoid the surrogate paradox when a validated surrogate is applied to a new trial with a new treatment or a new population. Let ACE Proposition 3 shows the relationships between the treatment effect on the surrogate and the treatment effect on the endpoint, which immediately give us the following implication relationships when the endpoint Y is unobservable.
Corollary 1. For trial r, we assume that the surrogate satisfies the causal necessity and ACE ss,r > 0.
(ii) Without monotonicity, ACE ss,r + ACEs s,r ≥ 0 and ACE
In Corollary 1(i), with monotonicity, a principal surrogate satisfying the causal sufficiency can avoid the surrogate paradox. Without monotonicity, the above result (i) does not hold since the causal effects on the endpoint Y may be different in the principal strata u = ss andss. Thus, we require the condition ACE ss,r + ACEs s,r ≥ 0 in (ii) of Corollary 1, i.e., the positive causal effect on the endpoint in stratum ss can offset the negative causal effect on the endpoint in stratumss.
Proposision 3 and Corollary 1 can help us to assess the treatment effect on the endpoint in a new trial both quantitatively and qualitatively. Below we illustrate this with Examples 3 and 4 for Cases 1 and 2 respectively.
Example 3. Suppose that in the validation trial, we studied drug A and obtained estimates ACE ss,r = ACEss ,r = 0, ACE ss,r = 0.5 and ACEs s,r = −0.4. For Case 1, we are aiming to evaluate the effect of the same drug on the disease for a different population in a new trial r . In trial r , we obtain E{S(1) | R = r } = 0.6 and E{S (0) 
If we only assume that ACE ss,r = ACEss ,r = 0 and ACE ss,r + ACEs s,r > 0 in the new trial as in the validation trial, then ACE Example 4. Suppose that in the validation trial, we studied drug A and estimated ACE ss,r = ACEss ,r = 0, ACE ss,r = 0.5 and ACEs s,r = −0.4. For Case 2, we are aiming to evaluate the effect of another drug B on the disease for the population in a new trial r . Unlike Case 1, we need to define the new drug as Z , the principal stratification as U = (S(Z = 1), S(Z = 0)), and the PSACEs as ACE ur = E{Y (Z = 1) − Y (Z = 0) | U = u, R = r }. In the new trial, we obtain E{S(1) | R = r } = 0.6 and E{S(0) | R = r } = 0.4. Similar to Example 3, if we assume that the PSACEs in the new trial are the same as those in the validation trial and monotonicity holds in the new trial, we can calculate ACE Y r = 0.1. If monotonicity fails, we can obtain the bounds (2) and (3) for ACE Y r . If we assume ACE ss,r = ACEss ,r = 0 and ACE ss,r + ACEs s,r > 0 as in Example 3, we can deduce that ACE Assuming the same values of PSACEs enables us to quantitatively evaluate the surrogate, and only assuming the same signs of PSACEs still allows us for qualitative evaluation. Note that we give only the sufficient conditions to evaluate the surrogate in a new trial. The plausibilities of these assumptions depend on subject knowledge and experts' opinions.
Simulation studies
In this section, we conduct simulation studies to evaluate finite sample performances of our proposed approaches, under both correctly specified and misspecified models.
Estimation under the models with homogeneity
We show the simulation results of the MLEs and the credible intervals of the PSACEs with and without monotonicity. The 95% credible intervals are obtained by the Gibbs Sampler with 20, 000 iterations and the first 4, 000 iterations as the burn-in period. We repeat 200 times to get the coverage proportions of the true PSACEs for each setting. We use three different sample sizes, and let N denote the average sample size for each trial, i.e., N = total sample size/N R . In Figures 1(a) and 1(b), we show the biases and root mean squared errors (RMSEs) of the MLEs and the coverage proportions of the posterior credible intervals only for ACE ss . The results for other principal strata are similar and shown in the online Appendix.
First, with monotonicity, we generate R from a categorical distribution with p r = 1/N R for all r. We generate Z from Bernoulli distributions conditional on R with different conditional probabilities, α, allowing for different treatment assignment probabilities for different trials. We generate U from categorical distributions conditional on R with probabilities (π ss,r , π ss,r , πss ,r ) for trial r. In order to satisfy Assumption 4, we choose U | R = r to depend on R = r. We generate three scenarios with N R = 2, 3 and 5, and present the true values of (π ss,r , π ss,r , πss ,r ) and α in the upper panel of Table 1 . We generate Y from Bernoulli distributions with the following conditional probabilities given Z and U : (δ 1,ss , δ 0,ss , δ 1,ss , δ 0,ss , δ 1,ss , δ 0,ss ) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1), with PSACEs ACE ss = 0.3, ACE ss = 0.4, and ACEss = 0.5.
We show the simulation results in Figure 1 (a), where the numbers "2," "3" and "5" denote the numbers of trials. The biases are small for all scenarios, the RMSEs decrease as the sample size and the number of trials increase, and the coverage proportions are close to 95% for all scenarios. Comparing the 6th point with the 7th point in the second subplot of Figure 1 (a), we can see that the Table 1 . True parameters in simulations. We present the values of πur = P (U = r | R = r) and αr = P (Z = 1 | R = r) in each scenario. The upper panel shows the true parameters with monotonicity, and the lower panel shows the true parameters without monotonicity.
With monotonicity NR = 2 NR = 3 NR = 5 (πss,r, πss,r, πss,r) αr (πss,r, πss,r, πss,r) αr (πss,r, πss,r, πss,r) αr r = 1 (0 The total sample sizes for these two cases are the same, while the case of the 6th point has more parameters (more π ur 's with more trials). The simulation is consistent with our intuition that more parameters will result in a larger RMSE. Next, without monotonicity, we generate R from a categorical distribution with p r = 1/N R for all r. We generate Z from Bernoulli distributions with conditional probabilities α, and U from categorical distributions both conditional on R with probabilities (π ss,r , π ss,r , πss ,r , πs s,r ) for trial r. For this case without monotonicity, the necessary condition for identifiability is N R ≥ 3. Thus we generate three scenarios with N R = 3, 4 and 5, and present the true values of (π ss,r , π ss,r , πss ,r , πs s,r ) and α in the lower panel of Table 1 . We generate Y from Bernoulli distributions with conditional probabilities given U and Z as (δ 1,ss , δ 0,ss , δ 1,ss , δ 0,ss , δ 1,ss , δ 0,ss , δ 1,ss , δ 0,ss ) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1, 0.5, 0.2), with PSACEs ACE ss = 0.3, ACE ss = 0.4, ACEss = 0.5, and ACEs s = 0.3.
We show the simulation results in Figure 1 (b), where "3," "4" and "5" denote the numbers of trials. The biases and the coverage proportions are similar to the cases with monotonicity. But the RMSEs become a little larger than those with monotonicity. The performances of our approaches are quite promising for the sample size N = 500 × N R , comparable to the ACCTs data set in Section 6.
Simulations under the models without homogeneity
We conduct simulation studies when the homogeneity assumption is false with δ zur dependent on r. Let d be a measure of heterogeneity. We simulate three cases for different levels of heterogeneity with d = 0.01, 0.025 and 0.05. For each case, we conduct simulation studies when N R = 3 both with and without monotonicity.
With monotonicity, we first generate (Z, U ) the same as the scenario with N R = 3 in the upper panel of Table 1 . To allow heterogeneity, we let δ zu1 = µ zu − (−1) z d, δ zu2 = µ zu and δ zu3 = µ zu + (−1) z d, with δ zur varying with r. The corresponding mean vector is (µ 1,ss , µ 0,ss , µ 1,ss , µ 0,ss , µ 1,ss , µ 0,ss ) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1).
Then we have ACE u1 = µ 1u − µ 0u + 2d, ACE u2 = µ 1u − µ 0u and ACE u3 = µ 1u − µ 0u − 2d. A larger d results in a larger violation of the homogeneity assumption. Similarly, without monotonicity, we first generate (Z, U ) the same as the scenario with N R = 3 in the lower panel of Table 1 . Then we let δ zu1 = µ zu −(−1) z d, δ zu2 = µ zu and δ zu3 = µ zu +(−1) z d, with the corresponding mean vector (µ 1,ss , µ 0,ss , µ 1,ss , µ 0,ss , µ 1,ss , µ 0,ss , µ 1,ss , µ 0,ss ) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1, 0.5, 0.2).
Then we have ACE u1 = µ 1u − µ 0u + 2d, ACE u2 = µ 1u − µ 0u , and ACE u3 = µ 1u − µ 0u − 2d.
For all the evaluations, we use the mean parameters µ zu as the "true parameters." Figures  1(c) and 1(d) show the results for ACE ss including the biases, the RMSEs of the MLEs and the coverage proportions of the posterior credible intervals, where "1," "2" and "3" correspond to the cases of d = 0.01, 0.025 and 0.05, respectively.
Comparing Figures 1(a) and 1(b) under the homogeneity assumption with Figures 1(c) and 1(d) without the homogeneity assumption, we find that the biases increase as d increases, and do not decrease as the sample size grows. The RMSEs increase and the coverage proportions of 95% credible intervals decrease as d increases, especially for large sample sizes. This means that the point and interval estimates are sensitive to the heterogeneity of trials. Thus, we will propose an approach for sensitivity analysis, and apply it to our real application in Section 7.
Application to the ACCTs data
For the ACCTs, the OS with five-year follow-up (survival status within 5 years) is used as the endpoint in most earlier papers to evaluate a particular treatment regimen. However, this endpoint requires five-year follow-up. The goal of the ACCTs study is to explore whether DFS with threeyear follow-up (cancer reoccurred before 3 years) is a valid surrogate for the OS with five-year follow-up. The data contain more than 20, 000 patients and 18 randomized III clinical trials. The period of trial enrollment spans from 1977 to 1999. The data of 10 of the randomized trials are available from Baker et al. (2012) . Baker et al. (2012) transformed the survival data into counts for binary outcomes. As a result, in each trial, we have a contingency table of observed frequencies with three variables: the treatment (Z), DFS (S) and OS (Y ). To illustrate our approaches, we assume all the trials have the same treatment and control, although we do not know the exact treatment and control in each trial. This may influence the plausibility of the homogeneity assumption, and thus we will conduct a sensitivity analysis in Section 7. We show all the bound analysis in the online Appendix, and find that the bounds are barely informative. In this section, we apply the proposed approaches to the ACCTs data to obtain point identifications of the treatment effects on the endpoint OS within principal strata defined by the potential DFS. We postpone the sensitivity analysis to Section 7.
Results with monotonicity
We use the Gibbs Sampler to simulate the posterior distributions of the PSACEs, because it is very direct to obtain posterior credible intervals for the PSACEs from draws of the Gibbs Sampler. After 100,000 iterations with 50,000 used as burn-in, the Markov chains converge very well with Gelman-Rubin diagnostic statistics approximately equal to 1 from five independent chains. Figure  2 (a) shows the histograms of the posterior draws of the PSACEs under monotonicity. The posterior median of ACEss, −0.008, is small, and its 95% credible interval covers zero. Although the posterior median of ACE ss , 0.032, is also small, its 95% credible interval does not cover zero. If we would like to believe monotonicity, there exists a "principal stratification direct effect" of the treatment on the endpoint for stratum ss but not for stratumss, and thus the causal necessity is not well satisfied. Because ACE ss is significantly nonzero with posterior median 0.583 and 95% credible interval (0.235, 0.787), and the treatment is effective on the surrogate with posterior medians of ACE S r greater than 0.022 in all trials, we can conclude that it is also effective on the endpoint according to Corollary 1 (i). Figure 2(b) shows the histograms of posterior draws of the PSACEs without monotonicity. First, ACE ss and ACEss are very close to zero with posterior medians 0.014 and 0.001 and 95% credible intervals covering zero. When the treatment does not affect the DFS with three-year follow-up, it will not affect the OS with five-year follow-up. Second, ACE ss and ACEs s are significantly different from zero with posterior medians 0.774 and −0.750 and 95% credible intervals excluding zero. Therefore, when the treatment affects the DFS with three-year follow-up, it will also affect the OS with five-year follow-up. The results without monotonicity differ from the results with monotonicity in the posterior distribution of ACE ss , which give us different interpretations about the causal mechanism. From a practical point of view, we need to verify which model is more plausible based on the observed data.
Results without monotonicity
Model comparison and checking
We use the methods described in Section 3.3 to perform model comparison. The ppp's are 0.039 and 0.470 under the models with and without monotonicity, respectively. Analogously, the p-values from the likelihood ratio tests are 0.015 and 0.140 under the models with and without monotonicity, respectively. Therefore, the model with monotonicity is not compatible with the observed data, and it is rejected by both frequentists' and Bayesian methods. Furthermore, the lower right subplot of Figure 2 (c) shows that the posterior medians and 95% credible intervals of πs s,r under the model without monotonicity are far from zero in many trials. On the contrary, the large p-values from both the likelihood ratio test and the posterior predictive check indicate very good fit of the model without monotonicity to the observed data. Although previous methods often assumed monotonicity, our tests reject it. Therefore, our methods can be used in a broader scope of applications and are more credible when monotonicity fails.
Evaluation of principal surrogate in the ACCTs data
According to the discussion in Section 5 about model checking, we believe that the model without monotonicity is more credible, and thus all our discussion below is based on the results in Section 6.2 from the model without monotonicity.
In Section 6.2, we obtain that the posterior medians of ACE ss and ACEss are very close to zero, and both of their 95% credible intervals cover zero, which means that the candidate surrogate satisfies the causal necessity very well. Therefore, our analysis verifies the causal necessity assumption in Baker et al. (2012) . In addition, the posterior medians of ACE ss and ACEs s are 0.772 and −0.748, respectively, with both of their 95% credible intervals excluding zero, showing that the surrogate also satisfies the causal sufficiency very well. We then have approximately ACE ss = 0, ACEss = 0, ACE ss > 0, and ACE ss + ACEs s ≥ 0. Thus, according to Corollary 1(ii), the surrogate paradox can be avoided by using this surrogate, i.e., if the treatment has a positive causal effect on the surrogate, it must have a positive causal effect on the endpoint. In fact, the treatment has a positive average causal effect on the surrogate (posterior medians of ACE S r are greater than 0.015 in all trials), and we can conclude that it has a positive average causal effect on the endpoint.
Sensitivity analysis without homogeneity
The homogeneity assumption is crucial for the identifiability of PSACEs. It may be violated if different trials with different environments may affect the endpoint. Instead of assuming that δ zur does not depend on r, we propose a Bayesian hierarchical model to account for the heterogeneity among δ zur for different trials. We keep the conditional distributions of P (R), P (Z | R) and P (U | R) unchanged, but assume the following hierarchical model for P (Y | Z, U, R):
In this model, deviation from the homogeneity assumption is characterized by the sensitivity parameter σ. When σ = 0, δ zur = δ zu and thus the homogeneity assumption holds. When σ > 0, the homogeneity assumption is violated. For example, when µ zu = logit(0.3) and σ = 0.5, the parameter δ zur falls in the interval (0.139, 0.533) with probability 0.95; when µ zu = logit(0.5) and σ = 0.5, the parameter δ zur falls in the interval (0.273, 0.727) with probability 0.95. Since the parameter δ zur is within the interval [0, 1], the above intervals imply quite large deviations away from the homogeneity assumption. Therefore, we choose 0.5 as the maximum value of the sensitivity parameter σ, and choose 0.05 and 0.2 as two moderate values of σ. In our Bayesian analysis, we choose the following priors:
∼ U (0, 1), {π ss,r , π ss,r , πss ,r , πs s,r } ∼ Dirichlet(1, · · · , 1), and µ zu ∼ U (−5, 5). We use the prior of µ zu for numerical stability, and also [logit We reanalyze the ACCTs data using the Bayesian hierarchical models with results shown in Figure 3 . Four rows correspond to the four principal strata (U = ss, ss,ss,ss), and three columns correspond to the three values of σ (σ = 0.05, 0.2, 0.5). For each subgraph, we draw the 2.5%, 50% and 97.5% posterior quantiles of PSACEs obtained from both the homogeneity model and Bayesian hierarchical models. The posterior distributions of PSACEs are robust for these different values of the sensitivity parameter σ, although the intervals become wider as σ increases. The signs of ACE ss and ACEs s remain positive and negative respectively, and the intervals of ACE ss and ACEss still cover zero. The results obtained by Bayesian hierarchical models remain unchanged by removing the homogeneity assumption, which show the robustness of our results in Section 6. 
Discussion
According to Frangakis and Rubin (2002) , evaluation of surrogates requires identification of the causal effects within principal strata. Because the potential outcomes of the surrogate endpoints under treatment and control cannot be jointly observed, the value of the principal stratification variable is missing. The monotonicity assumption excludes all the individuals with surrogate negatively affected by the treatment, which may not be biologically reasonable. The exclusion restriction assumption cannot be made when evaluating surrogates, because it implies the causal necessity and the validity of the causal necessity is a scientific question of interest. Unfortunately, the identifiability of the PSACEs are jeopardized without monotonicity or exclusion restriction. Although Bayesian analysis for weakly identified models still yields proper posterior distributions under proper priors, it may result in sensitive answers to the prior specification. The ACCTs data contain multiple independent trials for evaluating the same surrogate for the same endpoint. If we could make the homogeneity assumption across multiple trials, we can remove the monotonicity and exclusion restriction assumptions but still guarantee identifiability of the PSACEs. We find in the ACCTs data that both the "causal necessity" and the "causal sufficiency" hold, which imply that the DFS with three-year follow-up is a valid surrogate for OS with five-year follow-up. We investigate the applicability of the principal surrogate in new trials on new populations or with new treatments, and show that the surrogate in the ACCTs data could be a useful surrogate under some conditions. To remove the homogeneity assumption, we further propose an approach based on Bayesian hierarchical models, and investigate the sensitivity to the deviations from the homogeneity assumption. Within a reasonable range of the sensitivity parameter, the conclusions for the ACCTs data remain stable.
The framework we proposed could be applied to various settings involving post-treatment intermediate variables where the monotonicity and exclusion restriction assumptions are questionable. For example, in randomized experiments with non-compliance, the assignment of the treatment may influence the outcome directly. In these cases, we should concern the plausibility of exclusion restriction assumptions versus the plausibility of homogeneity assumptions. Models with the homogeneity assumption may sometimes be more flexible in practice. With the homogeneity assumption, we can test the monotonicity assumption. Furthermore, even if the homogeneity assumption does not hold, we can still conduct a sensitivity analysis as in Section 7.
Follmann (2006), Qin et al. (2008) and Mattei and Mealli (2011) proposed augmented designs for single trials to identify principal stratification causal effects using additional variables. From the perspective of experimental design, our approach can be viewed as an extension of Follmann (2006) , which imposes a stronger monotonicity assumption for the treatment effect on the intermediate variable. In our approaches, the number of trials R can be more general, as long as it satisfies the assumptions for identification. We can design experiments to create a variable R, satisfying these assumptions in order to identify the PSACEs. For example, in an encouragement experiment that encourages the patients to take their assignments, we can use different types of encouragement for different groups of people. Thus different groups will have different compliance behaviors, and the indicator for encouragement types then acts like R in our paper.
Several generalizations are possible. First, it is relatively easy to deal with a continuous endpoint because we can identify the distributional causal effect by dichotomizing the endpoint (Ding et al., 2011) . However, it is non-trivial to deal with a continuous surrogate endpoint since the causal necessity and sufficiency cannot be defined by dichotomizing it. Schwartz et al. (2011) set the stage for analyzing principal strata effects with continuous intermediate variables using a semiparametric Bayesian approach. Second, we discuss the methods and present an application without missing data, and dealing with the missing data problem will be of interest in many real applications. Finally, generalizing our approaches to longitudinal data and time-to-event data is also of theoretical and practical interest.
Supplementary Materials
Appendix A derives the bounds for the PSACEs both with and without monotonicity, and shows the application of these bounds to the ACCTs data. Appendix B provides the proofs for the propositions and theorems. Appendix C gives the computational details. Appendix D provides more details about the simulation studies.
We re-introduce all the notation used in the main text as follows:
Under the homogeneity assumption, we have:
We further define p = {pr : r = 1, . . . , NR}, α = {αr : r = 1, . . . , NR}, πr = {πss,r, πss,r, πss,r, πss,r}, π = {πr : r = 1, . . . , NR}, and δ = {δzu : z = 0, 1; u = ss, ss,ss,ss}.
Appendix A: Bounds for PSACEs
We need the following lemma to simplify the derivations of the bounds.
Lemma 1. Let X0 be a mixture of two Bernoulli distributions X1 and X2 with X0 ∼ αX1 + (1 − α)X2, Xi ∼ Bernoulli(pi), and a known mixing proportion α. Then we have
Proof of Lemma 1. See Cheng and Small (2006) . Since 0 ≤ πur ≤ 1, we can obtain the bounds for πss,r from Equations (A.11) to (A.13):
πss,r ∈ [max(0, P01r − P11r), min(P01r, P10r)] ≡ Rr.
From Lemma 1 and Equations (A.9) and (A.10), we can get the bounds of ACEss,r for a given πss,r:
Upper nm (ACEss,r | πss,r) = min 1, Q11rP11r P01r − πss,r − max 0, Q01rP01r − πss,r P01r − πss,r = min 1, Q11rP11r P01r − πss,r + min 0, (1 − Q01r)P01r P01r − πss,r − 1 , Lowernm(ACEss,r | πss,r) = max 0, Q11rP11r − P11r + P01r − πss,r P01r − πss,r − min 1, Q01rP01r P01r − πss,r = max 0, 1 − (1 − Q11r)P11r P01r − πss,r − min 1, Q01rP01r P01r − πss,r .
The bounds for ACEss,r can be obtained by maximizing or minimizing the above bounds over Rr, the feasible region of πss,r, namely,
Upper nm (ACEss,r) = max
is decreasing in πss,r, the above bounds can be simplified as Upper nm (ACEss,r) = min 1, Similarly, we can obtain the bounds of the other two principal strata. 2
Appendix A.3: Bounds for the ACCTs data
We compute bounds of the PSACEs for the 10 trials separately. Figure 5 shows the large sample bounds and confidence intervals for PSACEs based on the bootstrap (Cheng and Small, 2006) . Figure 5(b) shows that, without monotonicity, bounds of the PSACEs are barely informative. These bounds always contain zero, and bounds of ACEss,r and ACEss,r are [−1, 1], which are too wide for us to get any useful information. Figure 5 (a) shows that, with monotonicity, bounds are sometimes informative. But the confidence intervals for the PSACEs always contain zero, which do not provide strong evidence for the presence of causal effects. Standard resampling techniques, including the bootstrap, may be inconsistent and lead to confidence sets that are not asymptotically valid in a point-wise or uniform sense for drawing inference on partially identified quantities (Andrews, 2000; Andrews and Guggenberger, 2009; Romano and Shaikh, 2010 ). Here we follow Cheng and Small (2006) 's procedure to obtain the confidence intervals for the bounds, which is easy to implement. For more careful analysis, we can use the methods developed by Chernozhukov et al. (2013) . However, we do not do this here because calculating the bounds is not our primary goal. And what is more, the bounds are barely informative in our application.
Appendix B: Proofs of the propositions and theorems Appendix B.1: Proof of Proposition 1 in Section 3 Proposition 1. Under Assumption 1, Assumption 3 is equivalent to R Y | (U, Z), which implies ACEur = ACE ur for all u = ss, ss,ss,ss and r = r .
Proof of Proposition 1. Under randomization and homogeneity (Assumption 3), we have
and
for z = 0, 1; u = ss, ss,ss,ss; and r, r = 1, . . . , NR. Under homogeneity (Assumption 3), we have E{Y (z) | U = u, R = r} = E{Y (z) | U = u}, and thus ACEur = ACE ur , for z = 0, 1; u = ss, ss,ss,ss; and r, r = 1, . . . , NR. In addition, under randomization and homogeneity (Assumption 3), we have
and thus ACEu = δ1u − δ0u does not depend on r. Proof of Theorem 2. First, we can identify the proportions of all the principal strata under monotonicity. Let ω ys|zr = P (Y = y, S = s | Z = z, R = r) denote the probability of (Y = y, S = s) given (Z = z, R = r), which can be identified from the observed data.
The subpopulation with (Z = 1, S = 0) is equivalent to stratumss under treatment, and the subpopulation with (Z = 0, S = 1) is equivalent to stratum ss under control. Homogeneity (Assumption 3) implies that ω 10|1r = δ1,ss · πss,r and ω 11|0r = δ0,ss · πss,r, and therefore we can identify δ1,ss = ω 10|1r /πss,r and δ0,ss = ω 11|0r /πss,r from the observed data directly.
The subpopulation with (Z = 1, S = 1) is a mixture of two latent strata ss and ss, and under homogeneity (Assumption 3) we have: ω 11|1r = δ1,ss · πss,r + δ1,ss · πss,r.
For the two trials r1 and r2 satisfying Assumption 4(a) with πss,r 1 πss,r 2 = πss,r 1 πss,r 2 , we have: ω 11|1r 1 = δ1,ss · πss,r 1 + δ1,ss · πss,r 1 , ω 11|1r 2 = δ1,ss · πss,r 2 + δ1,ss · πss,r 2 , from which we can find a unique solution for (δ1,ss, δ1,ss): Similarly, the subpopulation with (Z = 0, S = 0) is a mixture of two latent strata ss andss, and under homogeneity (Assumption 3) we have:
ω 10|0r = δ0,ss · πss,r + δ0,ss · πss,r.
For the two trials r3 and r4 satisfying Assumption 4(b) with πss,r 3 πss,r 4 = πss,r 3 πss,r 4 , we have:
,ss · πss,r 3 + δ0,ss · πss,r 3 , ω 10|0r 4 = δ0,ss · πss,r 4 + δ0,ss · πss,r 4 , from which we can obtain a unique solution to (δ0,ss, δ0,ss): Proposition 2. Under Assumptions 1 and 3, a necessary condition for the local identifiability of the joint distribution of (Y, Z, S, U, R) is NR ≥ 3.
Proof of Proposition 2. The observed data of (R, Z, S, Y ) form an NR × 2 × 2 × 2 contingency table with (8NR − 1) free frequencies, therefore the saturated model contains (8NR − 1) parameters. The joint distributions contains (5NR + 7) parameters, with P (R) contributing (NR − 1) parameters, P (Z | R) contributing NR parameters, P (U | R) contributing 3NR parameters, and P (Y | Z, U ) contributing 8 parameters. Therefore, the model with monotonicity has (8NR − 1) − (5NR + 7) = (3NR − 8) degrees of freedom, which is positive when NR ≥ 3.
Example B.3.5. Suppose we have three trials. We set true parameters as (δ1,ss, δ0,ss, δ1,ss, δ0,ss, δ1,ss, δ0,ss, δ1,ss, δ0,ss) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1, 0.5, 0.2) , and display other parameters in Table B .3.1.
We can then get the observed distribution of P (Z = z, S = s, Y = y | R = r) as shown in Table B .3.2. By the homogeneity assumption, the probabilities of the observed data can be decomposed as
for z, s, y = 0, 1. Similar to the proof of Proposition 2, we can obtain that the number of parameters on the right-hand side of Equation (B.1) is 20. The observed distribution of (Z, S, Y | R) form a contingency table with 21 free frequencies on the left-hand side of Equation (B.1). We can use R package neqslv to solve these equations. We obtain that (δ1,ss, δ0,ss, δ1,ss, δ0,ss, δ1,ss, δ0,ss, δ1,ss, δ0,ss) = (0.8, 0.5, 0.7, 0.3, 0.6, 0.1, 0.5, 0.2) , which are the same as the true parameters.
Appendix B.4: Proof of Proposition 3 in Section 4
Proposition 3. For trial r, assume that the principal surrogate satisfies the causal necessity. Proof: With monotonicity, from the causal necessity ACEss,r = ACEss,r = 0, we have
Monotonicity also implies that ACE Without monotonicity, from the causal necessity, we have where I{·} is the indicator function. Let ξ (k) be the estimate of ξ after the k-th iteration.
In the E-step, we need to calculate n (k+1)
given the observed data and ξ (k) .
Under monotonicity, it is relatively straightforward to obtain that n 
0,ss,0,r = N000r
In the M-step, we update the parameters as follows:
Appendix C.2: EM algorithm without monotonicity
We can write the complete-data likelihood as
(1 − αr) n 0++r · u=ss,ss,ss,ss
In the E-step, we need to calculate n (k+1) zuyr = E(nzuyr | Nzsyr, ξ (k) ) given the observed data and ξ (k) as follows:
1,ss,0,r = N110r
1,ss,0,r = N100r
0,ss,0,r = N010r
, n In the M-step, we can update the parameters as follows:
Appendix C.3: Gibbs Sampler with monotonicity
We treat U as the missing data, and the Gibbs sampler iterates between the following imputation and posterior steps. In the imputation step, we draw U given the observed data and all the parameters. When (Zi = 1, Si = 0), we impute Ui =ss; when (Zi = 0, Si = 1), we impute Ui = ss; when (Zi = 1, Si = 1), we impute Ui as:
when (Zi = 0, Si = 0), we impute Ui as:
After imputing U , we can compute the frequencies of the complete data.
In the posterior step, we draw all the parameters given the complete data. Specifically, we draw the parameters from the following conditional distributions:
αr | · ∼ Beta(n1++r + 1, n0++r + 1), ∀r, (πss,r, πss,r, πss,r) | · ∼ Dirichlet(n+ss+r + 1, n+ss+r + 1, n+ss+r + 1), δzu | · ∼ Beta(nzu1+ + 1, nzu0+ + 1), ∀u, z.
Appendix C.4: Gibbs Sampler without monotonicity
We treat U as the missing data, and the Gibbs sampler iterates between the following imputation and posterior steps. In the imputation step, we draw U given the observed data and all the parameters. When (Zi = 1, Si = 1), we impute Ui as:
when (Zi = 1, Si = 0), we impute Ui as:
when (Zi = 0, Si = 1), we impute Ui as:
αr | · ∼ Beta(n1++r + 1, n0++r + 1), ∀r, (πss,r, πss,r, πss,r, πss,r) | · ∼ Dirichlet(n+ss+r + 1, n+ss+r + 1, n+ss+r + 1, n+ss+r + 1), δzu | · ∼ Beta(nzu1+ + 1, nzu0+ + 1), ∀z, u.
Appendix C.5: Gibbs Sampler for the Bayesian hierarchical model in Section 7
Define ηzur = logit(δzur), η = {ηzur : z = 0, 1; u = ss, ss,ss,ss}, and θ = (ξ, η). The complete data likelihood is
u=ss,ss,ss,ss
I{Ui ∈ O(Zi, Si)}.
αr | · ∼ Beta(n1++r + 1, n0++r + 1), ∀r, (πss,r, πss,r, πss,r, πss,r) | · ∼ Dirichlet(n+ss+r + 1, n+ss+r + 1, n+ss+r + 1, n+ss+r + 1),
(1 + e −ηzur ) n zu+r , ∀z, u, r.
The first three conditional distributions are standard. The fourth one is a truncated Normal distribution, which can be generated by applying the inverse of its cumulative distribution function to a Uniform(0, 1) random variable. The posterior distribution of ηzur is not standard, but fortunately its conditional density is log concave since
Therefore its posterior distribution is unimodal, and we can use the Metropolized Independence Sampler (Liu, 2001) to sample ηzur using a Normal proposal. We choose the proposal distribution as η ∼ N ( η, ψ), where η is the mode of the posterior distribution and ψ is the inverse of the Fisher information at the mode. Due to the log concave density, we can simply use the Newton-Raphson iteration to find the mode η.
Appendix D: More details about the simulation studies 
